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The phosphoprotein (P) of vesicular stomatitis virus (VSV) is a subunit of the viral RNA polymerase. In
previous studies, we demonstrated that insertion of 19 amino acids in the hinge region of the protein had no
significant effect on P protein function. In the present study, we inserted full-length enhanced green fluorescent
protein (eGFP) in frame into the hinge region of P and show that the fusion protein (PeGFP) is functional in
viral genome transcription and replication, albeit with reduced activity. A recombinant vesicular stomatitis
virus encoding PeGFP in place of the P protein (VSV-PeGFP), which possessed reduced growth kinetics
compared to the wild-type VSV, was recovered. Using the recombinant VSV-PeGFP, we show that the viral
replication proteins and the de novo-synthesized RNA colocalize to sites throughout the cytoplasm, indicating
that replication and transcription are not confined to any particular region of the cytoplasm. Real-time
imaging of the cells infected with the eGFP-tagged virus revealed that, following synthesis, the nucleocapsids
are transported toward the cell periphery via a microtubule (MT)-mediated process, and the nucleocapsids
were seen to be closely associated with mitochondria. Treatment of cells with nocodazole or Colcemid, drugs
known to inhibit MT polymerization, resulted in accumulation of the nucleocapsids around the nucleus and
also led to inhibition of infectious-virus production. These findings are compatible with a model in which the
progeny viral nucleocapsids are transported toward the cell periphery by MT and the transport may be
facilitated by mitochondria.
cesses have been hampered due to the inability to observe
these events by live-cell imaging of infected cells.
In a recent report, it was demonstrated that the fusion of the
viral envelope and the release of the nucleocapsid into the cytoplasm are two independent but successive steps in the endocytic
pathway of VSV infection (29). These studies revealed that
release of the viral nucleocapsid into the lumen of the endosomal vesicle occurs by the fusion of the viral envelope with the
membranes of the endosomes but that the nucleocapsid release into the cytoplasm may require a back-fusion event in
which the internal vesicles fuse with the membranes of the late
endosome (29). Following synthesis in the cytoplasm, the progeny nucleocapsids must then be transported to the plasma
membrane for viral assembly. The mechanism(s) by which the
transport of such large RNP complexes is accomplished is
unclear. Because of the high viscosity of the cytoplasm,
movement of the RNPs by diffusion is likely to be limited
(32). Intracellular pathogens and their macromolecular
components overcome this obstacle by hijacking cytoplasmic
motors and utilizing the cellular cytoskeleton as a roadway
for intracellular transport to reach their destination (23, 35,
49, 50).
An understanding of some of the mechanistic details of virus
entry by endocytic pathway and nucleocapsid release into the
cytoplasm of infected cells has been possible only with the use
of VSV chemically labeled with lipophilic fluorescent dyes
(29). The use of such labeled viruses is limited to studies
involving tracking of the input virus (16, 26, 29, 47). Once the
viral nucleocapsid is delivered into the cytoplasm, subsequent
tracking of the viral nucleocapsids, particularly, the sites of
synthesis and transport of the nucleocapsids to the sites of

Vesicular stomatitis virus (VSV) belongs to the family
Rhabdoviridae in the order Mononegavirales. VSV is an enveloped virus with a negative-stranded RNA genome of 11,161
nucleotides. The genome encodes for five viral proteins,
namely, nucleoprotein (N), phosphoprotein (P), matrix protein
(M), glycoprotein (G), and the RNA-dependent RNA polymerase (L) (1, 44). The viral genome is present within the
virion as a ribonucleoprotein (RNP) being tightly encapsidated
by the N protein and associated with the viral polymerase
complex of L and P proteins (1, 44). The M protein is located
underneath the viral envelope, whereas the G protein forms
spikes on the viral envelope. The G protein binds to the cell
surface receptor and is required for the entry of the virus into
the cells. The virus enters susceptible cells by receptor-mediated endocytosis. Fusion of the viral envelope with the endosomal membrane in a pH-dependent process leads to the release of the viral nucleocapsids into the cytoplasm for viral
gene expression. During VSV assembly, the progeny nucleocapsids are transported alone or in association with the viral M
protein to the plasma membrane, where they are packaged into
an envelope containing the viral G protein and are released
from the infected cells. Although some of the fundamental
steps in the VSV infection pathway have been deciphered,
many questions concerning the entry mechanisms and transport of viral nucleocapsids to synthesis sites and from synthesis
sites to assembly sites, as well as virus egress, remain poorly
understood. Studies to provide an understanding of these pro-
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idues 150 to 210). We recently studied the role of this hinge
region and found that it plays an important role in VSV RNA
synthesis and assembly of infectious particles (7). In that study,
we also demonstrated that insertion of 19 amino acids (aa)
within the hinge region of the protein (Fig. 1A) has no significant adverse effects on virus replication (7). In the present
study, we show that a fusion protein (PeGFP), in which fulllength enhanced green fluorescent protein (eGFP) was inserted in the hinge region of the P protein, is functional in viral
genome transcription and replication. A recombinant VSV
encoding the PeGFP protein in place of P protein (VSVPeGFP) was recovered. Using VSV-PeGFP, we have examined
the intracellular sites of viral RNA synthesis. By live-cell
imaging of VSV-PeGFP-infected cells, we have found that the
movement of newly synthesized viral nucleocapsids toward the
cell periphery is mediated by microtubules (MTs). In addition,
our studies indicate that mitochondria may play a role in intracellular transport of the viral nucleocapsids.
FIG. 1. Replication and transcription activities of PeGFP fusion
protein. (A) Domain organization of P protein, showing domains I, II,
and III and the hinge region. The site of eGFP incorporation at aa
position 196 is indicated by a vertical dotted line. (B) Expression of
PeGFP fusion protein in transfected cells. Cells transfected with plasmids encoding P (lanes 2 and 5) or PeGFP (lanes 3 and 6) proteins or
no plasmid (lanes 1 and 4) were radiolabeled with Expre35S35S label.
The radiolabeled proteins were immunoprecipitated with antibodies as
shown on the top (␣-P, anti-P; ␣-eGFP, anti-eGFP), analyzed by SDSPAGE, and detected by fluorography. Size markers in kDa are shown
on the left. P and PeGFP proteins are identified on the right. (C) Replication and transcription activities of PeGFP protein relative to Pwt as
determined by DI-particle replication or minigenome transcription
assays (20, 40). The histograms represent the average data from three
independent experiments, with standard deviations shown by error
bars. Repln, replication; Txn, transcription.

virion assembly, would require genetic tagging of the viral
nucleocapsid with fluorescent proteins.
VSV nucleocapsids are multiprotein-RNA complexes composed of viral RNA that is tightly wrapped with the N protein
and is associated with P and L proteins. P protein is a multifunctional protein that is an essential subunit of the viral RNAdependent RNA polymerase. In addition to its role in polymerase functions, it binds to the L protein and stabilizes it
from proteolytic degradation (4, 13); it acts as a chaperone for
the N protein, which then specifically encapsidates the viral
RNA (9, 34, 41); and it interacts with terminal sequences of
viral genome for viral RNA synthesis (21, 24). Our previous
studies showed that the protein is organized in a modular
fashion relative to its function (Fig. 1A) (6, 8, 19, 39). While
phosphorylation of specific amino acid residues at the aminoterminal domain I (amino acid residues 1 to 150) is responsible
for transcription activity (39), phosphorylation of specific
amino acid residues at the carboxy-terminal domain II (amino
acid residues 210 to 244) is important for optimal replication
activity (19) of P protein. Phosphorylation of these residues at
both domain I and domain II is indispensable for virus growth
(6). Domain III, which comprises 21 to 25 residues at the
extreme carboxy-terminal region, is important for mediating
the binding of P protein to the N RNA template (8). The
region that links domain I and domain II is called the hypervariable hinge region (approximately spanning amino acid res-

MATERIALS AND METHODS
Cell culture, viruses, antibodies, and reagents. Baby hamster kidney (BHK21) cells were maintained as described before (6, 7). Propagation and preparation of stocks of VSV, recombinant vaccinia virus expressing T7 RNA polymerase (vTF7-3) (15), and defective-interfering (DI) particles were carried out in
BHK-21 cells as described previously (40). Nocodazole (NOC), Colcemid, dimethyl sulfoxide (DMSO), 5-bromouridine 5⬘-triphosphate (BrUTP), and monoclonal antibody (MAb) against antitubulin (clone DM 1A) were from SigmaAldrich. NOC and Colcemid were reconstituted in DMSO; BrUTP was
reconstituted in water. Rabbit polyclonal antibody against VSV P protein, mouse
anti-VSV antibody, MAb against VSV N protein, and rabbit polyclonal antibody
against the NH2-terminal region of VSV L protein have been previously described (6, 46). Rabbit polyclonal antibody against eGFP was prepared in the
laboratory, and MAb against bromodeoxyuridine (BrdU) (clone BMC 9318) was
obtained from Roche Diagnostics. Secondary antibodies, goat anti-mouse Alexa488, goat anti-mouse Alexa-594, goat anti-rabbit Alexa-594, and MitoTracker
Red were obtained from Molecular Probes; donkey anti-mouse Cy5 and donkey
anti-rabbit Cy2 were from Jackson ImmunoResearch Laboratories.
Plasmid construction and virus recovery. The construction of plasmids Pwt
and PTn196 have been described in detail previously (7). Pwt is a plasmid
encoding the wild-type (wt) VSV (VSVwt) (Indiana serotype) P protein in
pGEM-3 vector (Promega) under the control of a T7 RNA polymerase promoter. The plasmid PTn196 is derived from Pwt by transposon-mediated mutagenesis and encodes the VSV P protein with a 19-aa insertion at residue 196.
The eGFP sequence was amplified by PCR using primers eGFPNotF3, 5⬘ATA
TATGCGGCCGCAATGGTGAGCAAGGGC3⬘, and eGFPNotR3, 5⬘ATATA
TGCGGCCGCCTTGTACAGCTCGTC3⬘, each containing a NotI site (underlined); pIRES2eGFP (Invitrogen) as a template; and Pfu polymerase (Stratagene).
The PCR product was digested with NotI and cloned at the unique NotI site in
PTn196. The resulting plasmid, PTneGFP, encodes a fusion protein (PeGFP) of 524
amino acids, compared to wt P protein, which is 265 amino acids long.
The P protein coding region in the plasmid pVSVFL(⫹), which contains the
full-length VSV genome (28), was replaced with the coding region for PeGFP
from PTneGFP by use of the EcoRV sites that flank the P gene, as described
previously (6). The resulting plasmid was designated pVSV-PeGFP, and the
recombinant virus recovered from this plasmid was named VSV-PeGFP. For the
generation of VSV encoding eGFP as an extra gene, an extra transcription unit
was incorporated in the pVSVFL(⫹) plasmid between the G and L noncoding
regions. The pVSVFL(⫹) plasmid was linearized with NheI, which is located
between the G and L noncoding regions. To generate the extra transcription unit,
two complementary oligonucleotides (FLVSVBsiWI⫹, 5⬘TATGAAAAAAACT
AACAGATATCCGTACG3⬘, and FLVSVBsiWI⫺, 5⬘CGTACGGATAT CTG
TTAGTTTTTTTCATA3⬘), incorporating a VSV poly(A)/termination signal, an
intergenic dinucleotide, and a transcription initiation signal followed by a unique
restriction site (BsiWI site is underlined), were designed. These oligonucleotides
were annealed and kinased and then ligated with the linearized pVSVFL(⫹)
plasmid, resulting in pVSVFLBsiWI. The eGFP coding region was amplified by
PCR using the primers eGFPBsiWIF, 5⬘ATATATCGTACGGCCACCATGGT
GAGCAAG3⬘, and eGFPBsiWIR, 5⬘ATATATCGTACGTTACTTGTACAGC
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TCGTC3⬘ (BsiWI site is underlined); digested with BsiWI; and cloned into
pVSVFLBsiWI. Recombinant VSV recovered from the resulting plasmid, pVSVeGFP, was named VSV-eGFP. The plasmids pN, pP, and pL (carrying the coding
sequences of the N, P, and L proteins of VSV, respectively, and the plasmid
p10BN), encoding a VSV minigenome, have been described previously (20, 38,
40). Recombinant viruses were recovered as described previously (6, 7).
Metabolic labeling and analysis of RNA. Metabolic labeling and analysis of
RNA in plasmid-transfected and virus-infected cells were performed as described previously (7, 20, 40). To examine transcription activity of mutant P
proteins, BHK-21 cells were infected with vTF7-3 and subsequently transfected
with p10BN, pN, and pL as well as Pwt or PTneGFP. RNAs were radiolabeled
in the presence of actinomycin D and analyzed by electrophoresis in agaroseurea gel. To examine replication activity of mutant P proteins, cells infected with
vTF7-3 and transfected with pN, pL, and Pwt or PTneGFP plasmids were
superinfected with DI particles, and RNAs were radiolabeled and analyzed as
described above. To examine the viral RNAs in infected cells, BHK-21 cells were
infected with either wt VSV or eGFP-tagged viruses and the RNAs were radiolabeled and analyzed as described above.
Metabolic labeling and analysis of viral proteins. Labeling of proteins in
transfected or virus-infected cells, immunoprecipitation using anti-VSV antibody
(1:200), anti-P antibody (1:200), and anti-eGFP antibody (1:200), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, and detection of proteins by fluorography were carried out as described previously (6, 7).
To examine proteins in virions, BHK-21 cells were infected with VSV at 1
PFU/cell and radiolabeled for 12 h at 4 h postinfection (hpi) with 100 Ci
Expre35S35S per ml of 90% Dulbecco’s modified Eagle’s medium (DMEM)
without methionine and cysteine and 10% regular DMEM. The virus from the
clarified culture supernatant was pelleted through a 10% sucrose cushion at
38,000 rpm in a Beckman SW41 rotor for 1 h at 4°C. The virus pellets were
resuspended, and viral proteins were analyzed by SDS-PAGE and detected as
described above.
Determination of single-step growth kinetics. Single-step growth kinetics of
mutant and wt viruses were determined in BHK-21 cells essentially as described
previously (6).
Drug treatment. Cells were pretreated with 10 g/ml NOC or Colcemid for 3 h
at 37°C and infected with viruses for 45 min at 4°C. The cells were washed and
incubated at 37°C in medium containing 10 M NOC or Colcemid. As controls,
NOC-untreated cells were maintained in media containing similar concentrations of DMSO.
BrUTP labeling of viral RNA. BHK-21 cells were infected with VSV-PeGFP at
a multiplicity of infection (MOI) of 10 PFU/cell and incubated for 2 h at 37°C.
BrUTP labeling of de novo-synthesized viral RNA was performed as described
previously (17), with minor modifications. Briefly, the infected cells were treated
with 15 g/ml of actinomycin D for 1 h at 2 hpi and transfected with BrUTP at
a final concentration of 10 mM by use of Lipofectamine 2000 in the presence of
actinomycin D for 2 h. The cells were fixed with 3.7% paraformaldehyde for 15
min at room temperature (RT) and processed for immunofluorescence for detection of viral RNA.
Fluorescence microscopy. For epifluorescence and differential interference
contrast (DIC) imaging, cells grown on glass coverslips or glass-bottomed cell
culture dishes (MatTek) were either fixed as described above or visualized
directly under an Olympus FV500/IX81 inverted confocal microscope. For immunofluorescence microscopy, the fixed cells were permeabilized with 0.1%
Triton X-100 for 15 min at RT or with 100% ethanol at ⫺20°C for 5 min. The
cells were blocked with phosphate-buffered saline with 0.05% Tween 20 containing 3% bovine serum albumin for 30 min at RT. The primary and secondary
antibodies diluted in phosphate-buffered saline with 0.05% Tween 20 containing
1% bovine serum albumin were added in succession after washing. The BrUTPlabeled RNAs were stained with an anti-BrdU MAb (1:10) followed by goat
anti-mouse Alexa-594 (1:500) containing 1 U/l of RNase inhibitor (RNase Out;
Invitrogen). The cells were stained with DAPI (4⬘,6⬘-diamidino-2-phenylindole)
and imaged using the inverted confocal microscope, and images were captured
with a charge-coupled-device camera.
For real-time visualization of nucleocapsid movement, cells grown in glassbottomed 35-mm dishes to 50% confluence were either treated with NOC or left
untreated and then infected with VSV-PeGFP as described above and the dish
was placed in a closed chamber maintained at 37°C and 5% CO2. Live-cell
imaging was performed using the inverted confocal microscope fitted with a
100⫻ lens. Images were captured at various times postinfection. For time-lapse
recording of the same sets of cells, images were collected at intervals of 10 to 15 s
for 30 min.
For staining of mitochondria, infected cells were washed thoroughly with
serum-free DMEM containing 25 mM HEPES buffer. MitoTracker Red diluted

J. VIROL.
in the above-described medium was added at 1 to 3 M, and the cells were
incubated at RT for 30 min. After being washed, the cells were maintained in
medium containing serum and placed in the closed chamber.

RESULTS
PeGFP fusion protein supports transcription and replication of VSV. Our recent observation (7) that insertion of 19 aa
at position 196 in the hinge region of P protein had no significant adverse effect on transcription and replication prompted
us to insert full-length eGFP coding sequence at this position
(Fig. 1A). To determine if the insertion resulted in a stable
protein, we examined the level of expression and the size of the
PeGFP fusion protein in transfected cells. Accordingly, BHK-21
cells were transiently transfected with plasmids encoding either
the wt or fusion proteins following vTF7-3 infection, and the
proteins were radiolabeled and examined by immunoprecipitation with anti-P and/or anti-eGFP antibody and SDS-PAGE. As
can be seen in Fig. 1B, the fusion protein PeGFP was stably
expressed, could be immunoprecipitated with both anti-P and
anti-eGFP antibodies, and possessed a predicted molecular mass
of ⬃73 kDa.
In order to examine the effect of eGFP insertion on P protein function in viral RNA synthesis, we used DI particles to
determine replication activity and a minigenome template
(p10BN) (20) to assess the transcription activity of PeGFP
fusion protein. The radiolabeled DI RNAs and minigenome
RNA were analyzed on urea-agarose gels and quantitated by
densitometry. Results from three independent experiments
show that the PeGFP protein is ⬃55% active in replication,
whereas it is ⬃22% active in transcription compared to the wt
P protein (Fig. 1C). These results suggest that the PeGFP
fusion protein is functional, albeit with reduced activity.
Recovery of infectious VSV encoding PeGFP fusion protein.
To test whether infectious virus could be recovered from VSV
genome plasmids encoding P protein into which eGFP was
inserted in frame in the hinge region, a recombinant VSV
genome plasmid (pVSV-PeGFP) encoding PeGFP in place of
wt P protein was constructed (Fig. 2A). We also constructed
another recombinant VSV genome plasmid (pVSV-eGFP),
containing eGFP coding sequence as an extra gene between
the G and L gene junctions (Fig. 2A). Both of these genomic
constructs led to recovery of recombinant VSV from transfected cells. In order to examine if the eGFP insertion into the
P open reading frame has any effect on the growth of the virus,
we examined single-cycle growth kinetics of the wt and mutant
viruses. As can be seen from Fig. 2B, VSV-eGFP grew to titers
similar to those of the wt VSV, whereas VSV-PeGFP grew to
titers that were on average 8- to 10-fold less than those of the
wt VSV. To determine if the viral growth correlated with the
extent of viral macromolecular synthesis in infected cells, we
examined RNA and viral protein synthesis in cells infected
with these viruses. Our results show that overall synthesis of
viral RNAs (Fig. 2C) and viral proteins (Fig. 2D) was not
significantly different from results obtained with cells infected
with wt VSV. These results indicate that in these mutant viruses the extent of viral protein and RNA synthesis did not
correlate with the viral growth rate. The sizes of the viral
mRNAs were as predicted, with the PeGFP mRNA migrating
more slowly than mRNA for wt P protein or eGFP (Fig. 2C,
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FIG. 2. Recovery and characterization of recombinant VSV encoding PeGFP fusion protein. (A) Recombinant VSV genome plasmids. VSVwt,
the wt VSV genome with the N, P, M, G, and L genes, shown in rectangular boxes; VSV-PeGFP, the VSV genome containing the PeGFP gene
in place of the wt P gene; VSV-eGFP, the VSV genome containing the eGFP gene as an extra cistron. Intergenic regions as well as 3⬘ leader gene
and 5⬘ trailer sequences are shown in black boxes; the eGFP coding region is shaded. (B) Single-cycle growth kinetics of mutant viruses. BHK-21
cells were infected with plaque-purified stocks of wt (VSVwt) or mutant (VSV-eGFP and VSV-PeGFP) viruses at an MOI of 20, and culture
supernatants were collected at the indicated time points. The viruses in the supernatants were quantitated by plaque assay. The average values from
four experiments are presented, with error bars representing standard deviations. (C) Analysis of VSV mRNAs in cells infected with the mutant
viruses. BHK-21 cells were infected with VSVwt (lane 1), VSV-PeGFP (lane 2), and VSV-eGFP (lane 3) at an MOI of 10. Viral RNAs were
radiolabeled, analyzed by electrophoresis, and detected by fluorography as described in Materials and Methods. Positions of the VSV mRNAs and
full-length genome are indicated at the right. Lane 3⬘ shows a longer exposure of the autoradiogram to clearly identify the eGFP mRNA that is
not readily visible in lane 3. (D) Analysis of proteins in cells infected with recombinant VSVs. BHK-21 cells were infected with VSVwt (lanes 2,
6, and 10), VSV-PeGFP (lanes 3, 7, and 11), and VSV-eGFP (lanes 4, 8, and 12) at an MOI of 10 or left uninfected (lanes 1, 5, and 9). The viral
proteins were radiolabeled for 1 h at 4 hpi, analyzed by SDS-PAGE as total (lanes 1 to 4) or immunoprecipitated with anti-P (␣-P) (lanes 5 to 8)
or anti-eGFP (␣-eGFP) (lanes 9 to 12) antibody, and detected by fluorography. The proteins are identified on the right.

compare lane 2 with lanes 1, 3, and 3⬘). As expected, six specific
proteins (N, P, M, G, eGFP, and L) were detected in cells
infected with VSV-eGFP (Fig. 2D, lane 4), whereas five proteins (N, PeGFP, M, G, and L) were detected in cells infected
with VSV-PeGFP (Fig. 2D, lane 3). Immunoprecipitation of
the proteins with anti-P (Fig. 2D, lanes 5 to 8) or anti-eGFP
(Fig. 2D, lanes 9 to 12) antibody resulted in detection of P,
PeGFP, and eGFP proteins of expected sizes from cells
infected with the appropriate recombinant viruses. The N
and L proteins and to some extent the M protein were also
immunoprecipitated with these antibodies. This is not surprising since the P protein interacts with N and L proteins
and is also associated with viral nucleocapsids that may
contain M protein.
Incorporation of reduced levels of PeGFP and L proteins
into virions. Since the overall size of PeGFP protein increased
by almost twofold (524 aa for PeGFP as opposed to 265 aa for
wt P protein), we were curious to examine what effect this
would have on the efficiency of incorporation of PeGFP into
VSV-PeGFP particles relative to other viral proteins as well as
relative to wt P protein in VSV. To test the efficiency of incorporation of the PeGFP fusion protein into VSV-PeGFP particles,

we radiolabeled the virus-infected cells with Expre35S35S, purified
the extracellular virions, and analyzed the proteins incorporated
into virions by SDS-PAGE analysis. Interestingly, we observed
that PeGFP and L proteins were incorporated consistently at
levels below that seen for wt VSV (Fig. 3). In these experiments, we examined viral proteins from all three viruses
(VSVwt, VSV-PeGFP, and VSV-eGFP) that correspond to
nearly equal amounts of N, M, and G proteins, the three major
structural proteins within the virions. Unequivocally, the data
shown in Fig. 3 and other similar independent experiments
suggested that PeGFP and L proteins were incorporated less
efficiently into VSV-PeGFP virions than into VSVwt and VSVeGFP virions. Taking into account the number of methionine
and cysteine residues in P and PeGFP proteins, we estimated
from three independent experiments that the amounts of
PeGFP and L proteins incorporated into the VSV-PeGFP
virions were on average about 50% of the amounts of the P and
L proteins in VSVwt. In the control virus expressing eGFP as
an extra gene (VSV-eGFP), the incorporation of L and P
proteins was similar to that of VSVwt. These results indicate
that the larger PeGFP protein may have influenced incorpo-
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FIG. 3. Incorporation of reduced levels of PeGFP and L proteins
into VSV-PeGFP. Viral proteins in infected cells were radiolabeled,
and the proteins incorporated into purified virions were analyzed by
SDS-PAGE and detected as described in the text. The positions of
various proteins are shown on the right.

ration of L-PeGFP protein complexes into the viral nucleocapsids that are packaged in the virions.
Examination of intracellular sites of viral RNA synthesis.
Subcellular localizations of eGFP were noticeably different in
cells infected with VSV-eGFP and VSV-PeGFP. While VSVeGFP-infected cells showed typical eGFP distribution evenly
throughout the cytoplasm as well as in the nucleus (Fig. 4A),
the fluorescence pattern in cells infected with VSV-PeGFP
appeared granular and the granules were distributed throughout the cytoplasm but not in the nucleus (Fig. 4B). The differential distribution patterns of PeGFP and eGFP likely reflect
the fact that PeGFP is associated with the viral nucleocapsids
and is intimately involved in viral genome replication and transcription, whereas eGFP is not.
To determine if the locations of the granular fluorescence
seen in cells infected with VSV-PeGFP represent the sites of
synthesis of viral RNA, we examined the sites of de novo
synthesis of viral RNA. Accordingly, cells infected with VSVPeGFP were treated with actinomycin D followed by BrUTP
to label de novo-synthesized RNA and examined by immunofluorescence using anti-BrdU antibody. Newly synthesized
RNA labeled with BrUTP was detected throughout the cytoplasm (Fig. 4D), and PeGFP protein (Fig. 4C) colocalized to
these sites (Fig. 4E). The viral N and L proteins also colocalized with the PeGFP protein (Fig. 4F to K) in a manner similar
to viral RNA. These data suggest that the de novo-synthesized
RNAs colocalize with the viral N, L, and PeGFP proteins,
indicating that synthesis of viral RNA occurs at these sites. The
sites of viral RNA synthesis appear to be distributed throughout the cytoplasm. The staining observed near the cell periphery may represent the viral nucleocapsids in transit to the cell
surface for assembly.

J. VIROL.

FIG. 4. Examination of sites of viral RNA synthesis in cells infected
with VSV-PeGFP. (A and B) Distribution of fluorescence in cells
infected with recombinant VSVs. BHK-21 cells infected with VSVeGFP (A) or VSV-PeGFP (B) at an MOI of 10 were fixed at 4 hpi,
stained with DAPI, and examined by fluorescence microscopy. (C to
E) Cells infected with VSV-PeGFP were labeled with BrUTP, and the
de novo-synthesized RNA was detected by MAb to BrdU and goat
anti-mouse Alexa-594. Colocalization of PeGFP (C) with RNA (D) is
shown in the merged image (E). (F to K) VSV-PeGFP-infected cells
were fixed at 4 hpi and stained with anti-N MAb (F to H) or anti-L
antibody (I to K) and the corresponding secondary antibodies conjugated to Alexa-594. Colocalization of N (G) or L (J) with PeGFP (F
and I) is shown in the merged images (H and K).

Association of viral nucleocapsids with mitochondria. Livecell imaging of VSV-PeGFP-infected cells revealed that many
green fluorescent dots were detectable as early as 30 min after
infection and became numerous by 1 to 2 hpi (data not shown).
A size estimation of several individual green dots suggested
that they represent individual viral nucleocapsids. Most of
these fluorescent nucleocapsids were mobile within the cytoplasm with time, moving toward the cell periphery away from
the nucleus. High-magnification DIC images of infected cells
showed that many of these nucleocapsids (Fig. 5A) appeared
to be moving along with or on mitochondrion-like structures.
Time-lapse imaging of one such nucleocapsid (Fig. 5A) indicated that the fluorescent nucleocapsids traversed along or in
close association with mitochondria or mitochondrion-like
structures in a nonlinear fashion toward the cell periphery (Fig.
5A0 to A210). Tracking of several such nucleocapsids (n ⫽ 12)
over time indicated that they moved with an average speed of
approximately 30 nm/s.
To confirm that the viral nucleocapsids were moving along
and/or associated with mitochondria, we examined the infected
cells treated with MitoTracker Red, which specifically stains
only mitochondria. By live-cell imaging, the green fluorescent
nucleocapsids were seen closely associated with the red-stained
mitochondria (Fig. 5B) and were moving along mitochondria
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FIG. 5. Live-cell tracking of VSV fluorescent nucleocapsid movement in infected cells. (A) BHK-21 cells were infected with VSV-PeGFP at
an MOI of 10, and at 2 hpi, the culture dish was transferred to a 37°C chamber with 5% CO2 and observed under an inverted laser scanning
microscope. A single infected cell and a small area (rectangular box) containing one fluorescent nucleocapsid were observed with time. Arrows in
this panel identify some nucleocapsids that are in close association with mitochondrion-like structures. Panels A0 to A210 are close-up images of
the small area showing the movement of a nucleocapsid (small arrow in A0) with time from the beginning (A0) to 30 s (A30), 60 s (A60), 90 s (A90),
120 s (A120), 180 s (A180), and 210 s (A210) of image recording. The direction of movement of the nucleocapsid (long arrows) toward the cell
periphery is shown. (B) Live-cell tracking of nucleocapsids in infected cells stained with MitoTracker Red, which specifically stains mitochondria.
The experiment was performed as described for panel A except that the infected cells were treated with MitoTracker Red for 30 min prior to image
recording. Arrows identify some nucleocapsids that are in close association with red-stained mitochondria. Panels B0 (beginning) to B50 (50 s) are
close-up images of the area boxed in panel B and represent the images recorded at times in seconds, as described for panels A0 to A210. Two
fluorescent nucleocapsids (identified by small arrow and arrowhead) are seen moving in close association with mitochondria (red). The long arrow
shows the direction of movement of the nucleocapsids toward the cell periphery.

with time (Fig. 5B0 to B50). Tracking of two such nucleocapsids
(Fig. 5B0 to B50) indicates that they are clearly seen very close
to, if not attached to, mitochondria. These results suggest that
mitochondria may be involved in transport of viral nucleocapsids from the sites of synthesis to the cell periphery.
Involvement of MTs in transport of progeny viral nucleocapsids. Since it is known that movement and intracellular
distribution of mitochondria are dependent on cytoskeletal
components, especially the MTs (18, 54), we investigated
whether MTs are involved in the observed movement of the
viral nucleocapsids. Initially, we examined the distribution of
fluorescent viral nucleocapsids in infected cells in the absence
or presence of NOC, a drug known to inhibit microtubule
polymerization. Cells not treated with the drug and infected
with VSV-PeGFP showed typical MT distribution in the cytoplasm (Fig. 6A). In these cells, the fluorescent viral nucleocapsids appeared to be concentrated on one side of the nucleus,
although nucleocapsids were also seen distributed throughout

the cytoplasm (Fig. 6A). This was representative of most infected cells. In addition, high-magnification images revealed
that many of these nucleocapsids were found to be closely
associated with MTs. Cells pretreated with NOC and infected
with VSV-PeGFP with continued presence of the drug showed
complete loss of MTs, and a different pattern of distribution of
viral nucleocapsids was observed (Fig. 6B). The vast majority
of the viral nucleocapsids were seen clustered around the nucleus as aggregates (Fig. 6B), although a small number of
individual nucleocapsids were also seen. These data suggest
that, in the absence of MTs, the majority of the nucleocapsids
are localized around the nucleus and fail to be transported
from these sites. A similar distribution of viral nucleocapsids
was observed with Colcemid (data not shown), which also
inhibits microtubule polymerization. The overall yield of extracellular virus from cells treated with NOC or Colcemid was
about 20% of that obtained from control untreated cells (Fig.
6C). The effect of the drugs on virus yield was not due to
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visible in the cytoplasm of untreated cells (Fig. 7A and B). In
contrast, nucleocapsids were seen in aggregates at 2 hpi (Fig.
7C) and became larger, brighter, and more numerous by 4 hpi
(Fig. 7D).
Immunostaining of infected cells with antitubulin antibody
in the presence of MitoTracker Red and with or without NOC
treatment further confirmed the involvement of MTs in the
transport of nucleocapsids. In the absence of NOC (Fig. 7E),
the nucleocapsids were dispersed throughout the cytoplasm
and largely remained as individual nucleocapsids, the majority
of which were associated with or in close proximity to MTs as
well as mitochondria (Fig. 7F and G). In cells treated with
NOC (Fig. 7H to J), aggregates of fluorescent nucleocapsids
were detected. Thus, the loss of MTs in NOC-treated cells led
to an accumulation of progeny viral nucleocapsids in the cytoplasm, resulting in the formation of these aggregates.
DISCUSSION

FIG. 6. Role of MTs in nucleocapsid transport. Untreated (A) or
NOC-treated (B) cells were infected with VSV-PeGFP, fixed at 4 hpi,
and stained with antitubulin antibody. MTs are stained red, while the
nucleocapsids appear in green. The nucleus stained with DAPI is
shown in blue. (C) Effect of NOC and Colcemid on virus yield. Cells
were either treated (⫹) with NOC or Colcemid or left untreated (⫺)
and then infected with VSV-PeGFP at an MOI of 10. The cell culture
supernatant was harvested at 12 to 14 hpi, and the virus yield was
determined by plaque assay. The average data from three independent experiments are presented, with standard deviations shown by
error bars.

reduced levels of viral protein synthesis or genome replication
(data not shown).
A time course experiment of untreated and NOC-treated
cells infected with VSV-PeGFP was performed to examine, by
live-cell recording, the synthesis of progeny nucleocapsids for
up to 4 h. Different patterns of fluorescence distribution were
observed in cells without and with NOC treatment. At the
beginning of infection, green fluorescence was barely detectable, but at 1 hpi, fluorescence was readily detectable in untreated and drug-treated cells and gradually increased in intensity with time. By 2 and 4 hpi, numerous nucleocapsids were

In recent years, the use of fluorescent molecules as protein
tags, combined with advanced imaging techniques, has been
instrumental in providing unprecedented opportunities for visualizing many dynamic processes in living cells (12, 27, 31). By
use of viruses genetically tagged with fluorescent proteins, several aspects of virus biology and virus-cell interactions in vitro
and in vivo have been examined. In particular, fluorescenttagged viruses were used to study intracellular transport of
human immunodeficiency virus capsids (35), capsid assembly
(36), and genome recombination (30, 43); herpes virus entry,
capsid transport, and egress (33, 45, 48); rhabdovirus gene
expression (14) and immune response (25); and morbillivirus
tissue tropism (53). In this report, we generated a recombinant
VSV encoding P protein fused in frame with eGFP (VSVPeGFP), which allowed us to track the movement of viral
nucleocapsids in infected cells by real-time imaging. Our results suggest that the nucleocapsids are synthesized at sites
distributed throughout the cytoplasm and that the progeny
nucleocapsids are transported to the cell periphery by an MTmediated process. Our observation that nucleocapsids are in
close proximity to mitochondria suggests that mitochondria
may also be involved in the nucleocapsid transport process.
Insertion of eGFP into the hinge region of the P protein led
to PeGFP fusion protein, which was active in viral genome
transcription and replication, indicating that the hinge region
can accommodate large insertions without much adverse effect
on protein function. However, incorporation of PeGFP as well
as the L protein into virions was affected (Fig. 3). It is possible
that the large size of the fusion protein might have sterically
hindered the association of P-L complexes with the viral N
RNA template, resulting in reduced incorporation of PeGFP
and L proteins in the virions. Although the levels of viral
macromolecular synthesis in cells infected with VSV, VSVPeGFP, or VSV-GFP were not significantly different from
each other, VSV-PeGFP grew to titers that were almost 10fold less than those of the other viruses. Whether the reduced
levels of incorporation of L and P proteins in VSV-PeGFP
account for its retarded growth phenotype remains to be examined. We have recently demonstrated that the P protein of
VSV plays a major role in assembly of infectious particles (7).
It is therefore possible that insertion of eGFP into P protein
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FIG. 7. Imaging of VSV-PeGFP-infected cells to demonstrate the effect on NOC on nucleocapsid transport. (A to D) DIC images of live cells
showing fluorescent nucleocapsid synthesis in infected cells at 2 (A and C) or 4 (B and D) hpi without (A and B) or with (C and D) NOC treatment.
The nucleus (n) is marked by a dotted oval. (E to G) Untreated cells infected with VSV-PeGFP were stained with MitoTracker Red at 4 hpi, fixed,
and immunostained with antitubulin antibody. VSV nucleocapsids (green), mitochondria (red), and MTs (pseudocolor blue) were visualized by
confocal fluorescence microscopy. The area in the square in panel E is magnified in panels F and G. Arrows in panel E show some nucleocapsids
in association with mitochondria. Arrows in panel F show some nucleocapsids directly on MT tracks. (H to J) Same as in panels E to G, but with
NOC treatment. The area in the square in panel H is magnified in panels I and J. Bars, 5 m (E and H) and 2 m (F, G, I, and J).

may have affected the assembly functions of the protein to
some extent, resulting in retarded growth of VSV-PeGFP. It
should be noted that a recombinant rabies virus encoding the
P protein with eGFP fused in frame at its amino terminus
possessed a significantly retarded growth phenotype (14). In
addition, eGFP incorporation into the L protein of measles
virus (11) led to a reduced growth phenotype of the recombinant virus. However, a recombinant rinderpest virus with insertion of eGFP at a similar location in the L protein grew like
the wt virus in vitro but was attenuated for growth and virulence in its natural animal host, cattle (2). Clearly, these data
indicate that growth and virulence properties can be altered by
insertion of eGFP into the viral polymerase. It will be interesting to examine whether VSV-PeGFP with insertion of
eGFP in the P protein of the viral polymerase complex possesses altered growth and virulence phenotypes in vivo.
In cells infected with VSV-PeGFP, the intracellular distribution of fluorescence was punctate. The majority of these
puncta were seen distributed throughout the cytoplasm, and
their locations represented the sites of viral replication since
the de novo-synthesized RNA as well as other components of
viral replication machinery, namely, the N and the L proteins,
colocalized to these sites. The interpretation that viral RNA
synthesis occurs throughout the cytoplasm but in proximity to
the cell nucleus was strengthened by the observation that in

cells treated with NOC or Colcemid, which inhibit MT polymerization, leading to a disruption of nucleocapsid transport
from the sites of synthesis to the cell periphery, the nucleocapsids were seen as aggregates around the nucleus (Fig. 6 and 7).
VSV contains approximately 450 copies of P molecules per
nucleocapsid (51). Although VSV-PeGFP contains almost half
as many PeGFP molecules as there are P molecules in wt VSV
(Fig. 3), it still has more than the 120 copies of eGFP necessary
to detect individual rotavirus particles (5). Clearly, by live-cell
imaging of infected cells at high magnification, we were able to
detect individual nucleocapsids as tiny green fluorescent structures (Fig. 5 and 6). Many of these green structures were of
uniform size, roughly approximating the size of viral nucleocapsids, although larger green dots, presumably representing
multiple nucleocapsids in very close proximity, were also observed in drug-untreated cells. These green structures were not
seen in cells expressing PeGFP alone or in combination with N
and/or L proteins (data not shown). Many of these fluorescent
nucleocapsids appeared to be associated with mitochondria
and moved in parallel with the longitudinal axis of mitochondria toward the cell periphery. The significance of the association of the nucleocapsid with mitochondria is not clear at this
time, but it is possible that cytoskeletal structures, like MTs,
that are used by mitochondria for their intracellular distribution (18, 54) might be involved in nucleocapsid transport. The
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association of nucleocapsids with mitochondria may thus be
transient and possibly serve as bridges linking MTs during
transport of the nucleocapsids. Alternatively, it is possible that
the association of nucleocapsids with mitochondria may be just
random. Further work will be necessary to provide any functional significance to the association of nucleocapsids with mitochondria.
Although the effect of NOC on nucleocapsid distribution
was dramatic (Fig. 6B), virus yield was reduced to about 20%
of that from untreated control cells (Fig. 6C). It is possible that
nucleocapsid transport may occur by additional mechanisms
that are independent of MT. In this regard, it is of note that for
DNA viruses whose capsids are specifically transported by MTs
toward the cell periphery, a 20 to 25% reduction in virus yield
in the presence of NOC has been considered to be significant
(3, 37). In the light of these observations, our data are consistent with the interpretation that MTs are involved in the transport of viral nucleocapsids by an anterograde movement toward the cell periphery. Although the nucleocapsid transport
toward the cell periphery was affected by NOC or Colcemid
treatment, virus entry and uncoating remained unaffected, as
seen by synthesis and accumulation of viral nucleocapsids with
time in NOC-treated cells (Fig. 7C and D). This is consistent
with the recent findings that NOC has no significant adverse
effect on VSV entry, uncoating, or viral macromolecular synthesis (29).
How might the MTs be involved in transport of viral nucleocapsids toward the cell periphery? Since the MTs form tracks
on which cellular cargos are transported by intracellular kinesin and dynein motors (10, 52), it is possible to envision a
scenario in which the nucleocapsids interact with kinesin
and/or dynein motors and are transported by these motors on
MT tracks. In this regard, it is interesting to note that the P
protein of rabies virus (another rhabdovirus) has been shown
to interact efficiently with the dynein light chain (14, 22, 42), a
component of the dynein motor. Although the significance of
this interaction in terms of intracellular transport of the viral
nucleocapsids has not been established, it is tempting to speculate that VSV nucleocapsids also interact with one or more
components of the intracellular motors that play a role in the
transport of the nucleocapsids mediated by MTs. With the availability of fluorescently tagged nucleocapsids, it will be possible to
study these interactions and examine intracellular events by realtime imaging of virus-infected cells for a better understanding
of the mechanisms by which the viral nucleocapsids are transported from the sites of synthesis to the assembly sites. Furthermore, VSV-PeGFP could be used to study entry and uncoating mechanisms that may provide significant insight into
receptor-mediated endocytosis and uncoating of viral nucleocapsids in infected cells.
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